scholarly journals Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level1,2

2016 ◽  
Vol 103 (2) ◽  
pp. 422-434 ◽  
Author(s):  
Silvia Sookoian ◽  
Gustavo O Castaño ◽  
Romina Scian ◽  
Tomas Fernández Gianotti ◽  
Hernán Dopazo ◽  
...  
Keyword(s):  
Liver Disease ◽  
Amino Acid ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Krebs Cycle ◽  
Nonalcoholic Fatty Liver ◽  
Serum Aminotransferases

scholarly journals Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease

Amino Acids ◽  
2014 ◽  
Vol 47 (3) ◽  
pp. 603-615 ◽  
Author(s):  
April D. Lake ◽  
Petr Novak ◽  
Petia Shipkova ◽  
Nelly Aranibar ◽  
Donald G. Robertson ◽  
...  
Keyword(s):  
Liver Disease ◽  
Amino Acid ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Amino Acid Metabolism ◽  
Acid Metabolism ◽  
Nonalcoholic Fatty Liver ◽  
Branched Chain Amino Acid ◽  
Branched Chain

Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease

Angiology ◽  
2021 ◽  
pp. 000331972110055
Author(s):  
Kerim Esenboğa ◽  
Alparslan Kurtul ◽  
Hüseyin Nazman ◽  
Cemre Gül Tekin ◽  
Nil Özyüncü ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Function Tests ◽  
Nonalcoholic Fatty Liver ◽  
Artery Disease ◽  
Stable Cad ◽  
Serum Aminotransferases ◽  
The Impact

Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology in the developed world. Nonalcoholic fatty liver disease is associated with a higher risk of cardiovascular disease. We investigated the impact of ranolazine on liver tests in patients with NAFLD and coronary artery disease (CAD). Patients who had established CAD and NAFLD (as assessed by raised serum transaminase activity, sonographic criteria, and the absence of any other obvious liver disease) were allocated to “on ranolazine” (n = 40) or “not on ranolazine” (n = 35) groups. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in all patients at baseline and at the end of the study. After 6 months of ranolazine treatment, both ALT and AST activities were significantly lower in patients in the “on ranolazine” group compared with “not on ranolazine” patients (change from baseline: ALT, −11.0 ± 1.7 IU/L, P < .001; AST, −5.2 ± 1.9 IU/L, P =.009). In conclusion, the present study showed that treatment with ranolazine for 6 months led to a significant reduction in the activities of both serum aminotransferases in patients with stable CAD and NAFLD.

Sign in / Sign up

Export Citation Format

Share Document